Dr. Patterson did not patent anything related to t
Post# of 148166
The press release says "Company files Pre-EUA with FDA for CCR5 receptor occupancy and a COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES" . I would guess the patent would be claiming this unique combination panel for diagnostics. This is likely unique since not many would have thought of a CCR5 receptor occupancy test unless they were working with Leronlimab. This would have nothing to do with owning any molecules, just a test panel.
All my opinion, of course.